 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Intravenous Administration In Combination With Gemcitabine - United Kingdom In June 2007, Oncolytics announced that it had started patient enrolment in a clinical trial in the U.K. using intravenous administration of REOLYSIN® in combination with gemcitabine. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN® when administered in combination with gemcitabine. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity. See related press releases and documents: June 11, 2007 - Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN®/Gemcitabine Trial January 3, 2007 - Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN® in Combination with Gemcitabine |
|
|||||||||||
 |
|
 |